Characterization of a Novel Bispecific Antibody That Activates T Cells


Journal

Monoclonal antibodies in immunodiagnosis and immunotherapy
ISSN: 2167-9436
Titre abrégé: Monoclon Antib Immunodiagn Immunother
Pays: United States
ID NLM: 101590955

Informations de publication

Date de publication:
Dec 2019
Historique:
entrez: 12 12 2019
pubmed: 12 12 2019
medline: 16 5 2020
Statut: ppublish

Résumé

Although CD3 T cell redirecting antibodies have been successfully utilized for the treatment of hematological malignancies (blinatumomab), the T cell signaling pathways induced by these molecules are incompletely understood. To gain insight into the mechanism of action for T cell redirection antibodies, we created a novel murine CD3xEpCAM bispecific antibody that incorporates a silent Fc to dissect function and signaling of murine CD8 OT1 T cells upon stimulation. T cell-mediated cytotoxicity, cytokine secretion, expression of activation markers, and proliferation were directly induced in T cells treated with the novel CD3xEpCAM bispecific molecule

Identifiants

pubmed: 31825302
doi: 10.1089/mab.2019.0035
pmc: PMC6918852
doi:

Substances chimiques

Antibodies, Bispecific 0
CD3 Complex 0
Epithelial Cell Adhesion Molecule 0
Immunoglobulin Fc Fragments 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

242-254

Références

Blood Cancer J. 2015 Aug 21;5:e340
pubmed: 26295610
Immunology. 2009 Feb;126(2):165-76
pubmed: 19125887
J Leukoc Biol. 1996 Aug;60(2):278-84
pubmed: 8773590
Cell. 1994 Jan 14;76(1):17-27
pubmed: 8287475
Nat Protoc. 2014 Oct;9(10):2450-63
pubmed: 25255089
Nature. 2017 Jul 13;547(7662):217-221
pubmed: 28678778
BioDrugs. 2014 Aug;28(4):331-43
pubmed: 24638872
JCI Insight. 2018 May 17;3(10):
pubmed: 29769444
Mol Cancer Ther. 2018 Apr;17(4):776-785
pubmed: 29339550
J Med Virol. 2016 Jan;88(1):13-20
pubmed: 26104380
J Immunol. 2014 Mar 1;192(5):2143-55
pubmed: 24501199
Cancer Cell. 2017 Mar 13;31(3):383-395
pubmed: 28262555
J Immunol. 2015 May 1;194(9):4073-80
pubmed: 25888703
Nature. 1985 Apr 18-24;314(6012):628-31
pubmed: 2859527
Exp Hematol Oncol. 2017 May 2;6:12
pubmed: 28469973
Biosci Rep. 2000 Aug;20(4):213-37
pubmed: 11092246
Curr Opin Mol Ther. 2008 Jun;10(3):273-84
pubmed: 18535935
Am J Pathol. 1979 Dec;97(3):587-600
pubmed: 507192
Nature. 1985 Jul 25-31;316(6026):354-6
pubmed: 3160953
J Immunol. 1987 Aug 15;139(4):1369-74
pubmed: 3112233
Antibodies (Basel). 2017 Sep 01;6(3):null
pubmed: 31548527
Cancer Immunol Immunother. 2006 Jul;55(7):785-96
pubmed: 16187083
Pharmacol Ther. 2018 Feb;182:161-175
pubmed: 28834699
Mol Cancer Ther. 2019 Feb;18(2):312-322
pubmed: 30381448
Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5145-50
pubmed: 23479652
Sci Transl Med. 2017 Oct 4;9(410):null
pubmed: 28978751
Blood. 2015 Dec 10;126(24):2578-84
pubmed: 26480933
Cancer Res. 2015 Jul 1;75(13):2587-93
pubmed: 26069246
Haematologica. 2013 Dec;98(12):1930-8
pubmed: 23812940
Int Immunol. 1999 Jul;11(7):1085-92
pubmed: 10383941
Breast Cancer Res Treat. 2017 Nov;166(2):641-650
pubmed: 28798985
J Mol Recognit. 2012 Mar;25(3):136-46
pubmed: 22407977
Mol Immunol. 2006 Feb;43(6):763-71
pubmed: 16360021
Int Immunol. 2018 Feb 3;30(1):13-22
pubmed: 29294043
Clin Immunol. 2008 Apr;127(1):107-18
pubmed: 18222733
MAbs. 2014;6(6):1571-84
pubmed: 25484061
Biomedicines. 2015 Dec 02;3(4):282-303
pubmed: 28536413
J Immunol. 2017 May 15;198(10):3939-3948
pubmed: 28424242
J Immunol. 2004 May 1;172(9):5159-67
pubmed: 15100252
Proc Natl Acad Sci U S A. 1987 Mar;84(5):1374-8
pubmed: 2950524
J Invest Dermatol. 2014 Jul;134(7):1884-1892
pubmed: 24468748
Sci Rep. 2017 May 30;7(1):2476
pubmed: 28559564
Nat Rev Drug Discov. 2019 Aug;18(8):585-608
pubmed: 31175342

Auteurs

Olesya Chornoguz (O)

Janssen Biotherapeutics, Janssen R&D, Spring House, Pennsylvania.

Catherine N Leettola (CN)

Janssen Biotherapeutics, Janssen R&D, Spring House, Pennsylvania.

Karen Leander (K)

Janssen Biotherapeutics, Janssen R&D, Spring House, Pennsylvania.

Kerry Brosnan (K)

Janssen Biotherapeutics, Janssen R&D, Spring House, Pennsylvania.

Eva Emmell (E)

Janssen Biotherapeutics, Janssen R&D, Spring House, Pennsylvania.

Mark L Chiu (ML)

Janssen Biotherapeutics, Janssen R&D, Spring House, Pennsylvania.

Sandra Santulli-Marotto (S)

Janssen Biotherapeutics, Janssen R&D, Spring House, Pennsylvania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH